Who’s Who in American CMT Fundraising and Research

Line drawing of a timeline of people's roles as horizontal bars, several overlapping in the same years, with a red dashed line marking one overlap.

The CMT charities with the biggest funds are American. They are run, advised, and funded by a small circle of people, and some of them also hold roles in companies the charities invest in or partner with. This timeline lines up those roles year by year, so the overlaps are visible at a glance.

Every bar on the timeline comes from cmt.blog’s reporting and a primary record it cites: tax returns, state filings, company disclosures, the charities’ own pages, and people’s own profiles. A faded endpoint means a start or end date isn’t on record. The list after the chart shows every role with its source.

Holding roles in more than one organization isn’t necessarily illegal or unethical. The people best placed to advise a CMT charity are often the people doing CMT research. The question the Sunlight on the CMTA series asks is whether donors can see these overlaps, and who steps aside noting conflict of interests when they arise.

For the charities themselves and what they spend, see CMT Charities Around the World. If you feel a role described here is inaccurate or something is missing, tell me.

A timeline of American CMT research and philanthropy leadership

  • Charity role
  • Company role
  • Charity advisory board
  • University or professional society
  • Faded end: date approximate
  • On record that year only
Timeline of roles held by people in the US CMT charities, from 2004 to 2026. The list after the chart gives every role with its source.Key eventsLivney becomes CMTA CEO (2011). Source: CMTA Forms 990, tax years 2008 to 2019, Part VII (scans on ProPublica Nonprofit Explorer); CMTA, Stanford Patient & Family Conference program, September 27, 2014Livney becomes CMTA CEO (2011)CMTRF founded. Source: a forthcoming cmt.blog postCMTRF foundedCMTA sues CMTRF over donor list. Source: a forthcoming cmt.blog postCMTA sues CMTRF over donor listTaysha–CMTA–HNF GAN testing. Source: a forthcoming cmt.blog postTaysha–CMTA–HNF GAN testingCMTA has no chief executive (Apr.–Oct. 2023). Source: CMTA Forms 990, tax years 2017 to 2023, Part VII and Schedule J (ProPublica Nonprofit Explorer)CMTA has no chief executive (Apr.–Oct. 2023)CMTA venture arm’s first investment. Source: a forthcoming cmt.blog postCMTA venture arm’s first investmentShark Tooth incorporated. Source: cmt.blog: Shark Tooth: The CMTA’s Stake in a Board Member’s BiotechShark Tooth incorporatedCure CMT sues HNF. Source: a forthcoming cmt.blog postCure CMT sues HNFPatrick LivneyPatrick Livney: CMTA: director. On the board from about 2005, its president by 2008. Still listed as a director on the 2012 return, not on the 2013 one. Source: CMTA, Stanford Patient & Family Conference program, September 27, 2014; CMTA Forms 990, tax years 2008 to 2019, Part VII (scans on ProPublica Nonprofit Explorer)CMTA: directorPatrick Livney: CMTA: chief executive. The CMTA’s 2014 program says he took office in December 2011, but its 2011 return already lists him as chief executive, paid $117,019 that year. Last listed on the 2016 return, at $325,000; the 2017 return names Amy Gray. Source: CMTA, Stanford Patient & Family Conference program, September 27, 2014; CMTA Forms 990, tax years 2008 to 2019, Part VII (scans on ProPublica Nonprofit Explorer)CMTA: chief executivePatrick Livney: CMT Research Foundation: co-founder, chair. Co-founded April 2018; chaired it “for six years,” by his account. Source: a forthcoming cmt.blog postCMT Research Foundation: co-founder, chairPatrick Livney: Cure CMT: founder, runs it. Applied for the CURE CMT trademark August 21, 2024; the charity launched May 2025. Source: a forthcoming cmt.blog postCure CMT: founder, runs itPatrick Livney: CMTA board chairman and president (Oct. 2008). Source: CMTA press release, “Charcot-Marie-Tooth Association Expands Board of Directors,” October 29, 2008 (Wayback Machine)CMTA board chairman and president (Oct. 2008)David HallDavid Hall: CMTA: chief executive. Listed as chief executive on the 2010 and 2011 returns, paid $190,000 in 2010 and $130,625 in 2011, the year Livney took over. Source: CMTA Forms 990, tax years 2008 to 2019, Part VII (scans on ProPublica Nonprofit Explorer)CMTA: chief executiveSusan RuedigerSusan Ruediger: CMTA: director of development. Eight years in the role; last day January 2018. Source: a forthcoming cmt.blog postCMTA: director of developmentSusan Ruediger: CMT Research Foundation: co-founder, chief executive. Co-founded the foundation in April 2018 and is its chief executive. Source: cmt.blog: Who Writes the Rules for CMT Drug Trials?CMT Research Foundation: co-founder, chief executiveTom DubenskyTom Dubensky: CMTA: director. LinkedIn: board member June 2016 to March 2026. On CMTA tax returns from 2017. Source: cmt.blog: Tom Dubensky, the CMTA’s Venture Arm, and Shark ToothCMTA: directorTom Dubensky: ImmuneSensor Therapeutics: chief executive. Became CEO in May 2024; LinkedIn lists him as president and CEO until September 2026. Source: cmt.blog: Tom Dubensky, the CMTA’s Venture Arm, and Shark Tooth; cmt.blog: Sunlight on the CMTA: The Series So FarImmuneSensor Therapeutics: chief executiveTom Dubensky: CMTA special adviser (Winter 2025 report). Source: cmt.blog: Tom Dubensky, the CMTA’s Venture Arm, and Shark ToothCMTA special adviser (Winter 2025 report)Tom Dubensky: Shark Tooth scientific adviser (listed 2026). Source: cmt.blog: Tom Dubensky, the CMTA’s Venture Arm, and Shark ToothShark Tooth scientific adviser (listed 2026)David AppleDavid Apple: CMTA: director. Listed as “Director (from Apr. 2023).” Source: cmt.blog: Tom Dubensky, the CMTA’s Venture Arm, and Shark ToothCMTA: directorDavid Apple: Shark Tooth Biotech: founder, chief executive. Incorporated in Delaware September 23, 2024. The CMTA held a $248,763 stake in 2025. Source: cmt.blog: Shark Tooth: The CMTA’s Stake in a Board Member’s Biotech; cmt.blog: Canada’s CMT1A Research Partnership: Who Funds It, and Who Gets the Rights?Shark Tooth Biotech: founder, chief executiveSteven GraySteven Gray: CMTA Scientific Advisory Board: member. On the board since 2018. Source: a forthcoming cmt.blog postCMTA Scientific Advisory Board: memberSteven Gray: Taysha Gene Therapies: scientific founder, chief scientific adviser. Named in Taysha’s September 2020 S-1. End date not on record. Source: a forthcoming cmt.blog postTaysha Gene Therapies: scientific founder, chief scientific adviserSteven Gray: Elpida Therapeutics: board of directors. On Elpida’s board by June 2023. The CMTA funds an Elpida CMT4J study and holds a $150,000 Elpida note. Source: a forthcoming cmt.blog postElpida Therapeutics: board of directorsMichael ShyMichael Shy: CMTA Clinical Expert Board: co-chair. Co-chair since 2008. Source: a forthcoming cmt.blog postCMTA Clinical Expert Board: co-chairMichael Shy: Peripheral Nerve Society CMT consortium: board chair. Chaired the CMTR board 2019 to 2021. Source: a forthcoming cmt.blog postPeripheral Nerve Society CMT consortium: board chairMichael Shy: CMTA: director. Listed as a director on the returns for 2008 to 2016, except 2015’s, which leaves him out. Not listed from 2017. Source: CMTA Forms 990, tax years 2008 to 2019, Part VII (scans on ProPublica Nonprofit Explorer)CMTA: directorMichael Shy: CMTA: director. Back on the board of directors from 2023. Leads the CMTA-funded Inherited Neuropathy Consortium at Iowa. Source: a forthcoming cmt.blog postCMTA: directorSteven SchererSteven Scherer: CMTA: director. Joined the board in October 2008. Listed as a director through the 2016 return, except 2015’s. Not listed from 2017. Source: CMTA press release, “Charcot-Marie-Tooth Association Expands Board of Directors,” October 29, 2008 (Wayback Machine); CMTA Forms 990, tax years 2008 to 2019, Part VII (scans on ProPublica Nonprofit Explorer)CMTA: directorSteven Scherer: CMTA Scientific and Clinical Expert Boards: member. On both boards since 2008. Source: a forthcoming cmt.blog postCMTA Scientific and Clinical Expert Boards: memberSteven Scherer: CMTA: director. On the board of directors again from 2023. Source: a forthcoming cmt.blog postCMTA: directorSteven Scherer: On Shark Tooth’s team page (2026). Source: cmt.blog: Shark Tooth: The CMTA’s Stake in a Board Member’s BiotechOn Shark Tooth’s team page (2026)John SvarenJohn Svaren: CMTA Scientific Advisory Board: chair. Chair since 2015. Source: a forthcoming cmt.blog postCMTA Scientific Advisory Board: chairJohn Svaren: CMTA: director. Listed as a director on the returns for 2011 to 2016, except 2015’s. Not listed from 2017. Source: CMTA Forms 990, tax years 2008 to 2019, Part VII (scans on ProPublica Nonprofit Explorer)CMTA: directorJohn Svaren: CMTA: director. Back on the board of directors from 2023. Source: a forthcoming cmt.blog postCMTA: directorJohn Svaren: Shark Tooth scientific adviser (listed 2026). Source: cmt.blog: Canada’s CMT1A Research Partnership: Who Funds It, and Who Gets the Rights?Shark Tooth scientific adviser (listed 2026)Taleen HananiaTaleen Hanania: CMTA Scientific Advisory Board: member. On the board since 2014. Source: a forthcoming cmt.blog postCMTA Scientific Advisory Board: memberTaleen Hanania: PsychoGenics chief commercial officer (start not on record). Source: a forthcoming cmt.blog postPsychoGenics chief commercial officer (start not on record)Glenn PfefferGlenn Pfeffer: Cure CMT: board member. On Cure CMT’s board; Cure CMT launched May 2025. Source: a forthcoming cmt.blog postCure CMT: board memberGlenn Pfeffer: CMTA board of directors (2015). Source: a forthcoming cmt.blog postCMTA board of directors (2015)Glenn Pfeffer: CMTA advisory board (current). Source: a forthcoming cmt.blog postCMTA advisory board (current)Amy GrayAmy Gray: CMTA: chief executive. Named chief executive in May 2017; left in March 2023 with $105,769 in severance. Paid $250,000 in 2018, rising to $269,038 by 2022. Source: CMTA Forms 990, tax years 2017 to 2023, Part VII and Schedule J (ProPublica Nonprofit Explorer)CMTA: chief executiveSue BruhnSue Bruhn: CMTA: chief executive. Joined November 2023. Source: cmt.blog: Who Is Behind the CMTA?CMTA: chief executiveSue Bruhn: Earlier: CEO of three biotech companies. Promedior, Proclara Biosciences, and Tiaki Therapeutics; years not on record. Source: cmt.blog: Who Is Behind the CMTA?Earlier: CEO of three biotech companies
Dates come from cmt.blog reporting and the primary records it cites. Hover over a bar for its source. Checked November 20, 2026.
Every role, with sources